Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YAQ001
- Development stage
- Preclinical
- Lead developer
- Yaqrit
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
YAQ001 (Carbalive) is an orally administered, non-absorbable medical device developed by Yaqrit for the treatment of advanced liver disease, specifically decompensated cirrhosis. It consists of highly engineered, nanoporous carbon beads with a dual pore structure (macroporous and microporous) designed to selectively adsorb and remove lipopolysaccharides (LPS), bacterial toxins, and inflammatory molecules from the gastrointestinal tract. By restricting its action to the gut, YAQ001 modulates the gut microbiome ecosystem, increasing beneficial bacteria while suppressing pathogenic taxa and inhibiting biofilm formation. This approach aims to reduce systemic inflammation and prevent the progression of cirrhosis without killing beneficial bacteria. In Europe, it is classified as a medical device and is also being investigated for irritable bowel syndrome (IBS).
- Brand names
- Carbalive
Beyond the preview
Go deeper on YAQ001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YAQ001.